Cargando…

BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up

(1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donze, Caroline, Min, Victoria, Ninove, Laetitia, de Lamballerie, Xavier, Revon Rivière, Gabriel, Verschuur, Arnauld, Saultier, Paul, André, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224057/ https://www.ncbi.nlm.nih.gov/pubmed/37243093 http://dx.doi.org/10.3390/vaccines11050989

Ejemplares similares

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience
por: Revon-Riviere, Gabriel, et al.
Publicado: (2021)

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population
por: Malissen, Nausicaa, et al.
Publicado: (2021)

Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas
por: Papalia, Honoré, et al.
Publicado: (2018)

A Randomized Trial of Physical Activity in Children and Adolescents with Cancer
por: Saultier, Paul, et al.
Publicado: (2021)

Blood-Derived Liquid Biopsies Using Foundation One(®) Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience
por: Cahn, Fanny, et al.
Publicado: (2022)

A sport room within the paediatric oncology ward
por: Revon-Rivière, Gabriel, et al.
Publicado: (2021)

Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
por: Rico, Audrey, et al.
Publicado: (2021)

Necrotic ulcerated and bleeding striae distensae following bevacizumab in a palliative setting for gliobastomatosis cerebri
por: Laugier, Olivia, et al.
Publicado: (2017)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease
por: Shoji, Kensuke, et al.
Publicado: (2023)

Prospective and retrospective evaluation of the Cepheid Xpert® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus
por: Salez, Nicolas, et al.
Publicado: (2015)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Persistance à six mois des réponses immunitaires induites par une vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2 – cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
por: Olson, Samantha M., et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
por: Lam, Chi-Yan, et al.
Publicado: (2023)

BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar
por: Musa, Sarah, et al.
Publicado: (2021)

Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
por: Oliveira, Carlos R., et al.
Publicado: (2022)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
por: Mansanguan, Suyanee, et al.
Publicado: (2022)

Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors
por: Gallian, Pierre, et al.
Publicado: (2020)

Pilot study of a pediatric metronomic 4-drug regimen
por: André, Nicolas, et al.
Publicado: (2011)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male
por: Sutcu, Murat, et al.
Publicado: (2022)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s48opanru4t0i0t2q3bqb4dpsf